ABSTRACTS


Abstracts Nanomedicine Review


Nanotechnology for enrichment and detection of circulating tumor cells


Saheel Bhana1 1


, Yongmei Wang1 & Xiaohua Huang1


Department of Chemistry, The University of Memphis, Memphis, TN, USA


Nanomedicine (Lond.) 10(12), 1973–1990 (2015). 12


Circulating tumor cells (CTCs) are a hallmark of invasive behavior of cancer, responsible for the development of metastasis. Their detection and analysis have significant impacts in cancer biology and clinical practice. However, CTCs are rare events and contain heterogeneous subpopulations, requiring highly sensitive and specific techniques to identify and capture CTCs with high efficiency. Nanotechnology shows strong promises for CTC enrichment and detection owning to the unique structural and functional properties of nanoscale materials. In this review, we discuss the CTC enrichment and detection technologies based on a variety of functional nanosystems and nanostructured substrates, with the goal to highlight the role of nanotechnology in the advancement of basic and clinical CTC research.


Future Oncology Review


EGFR mutations in lung cancer: from tissue testing to liquid biopsy Francesca Fenizia1


Alessandra Sacco1 Iannaccone1


, Antonella De Luca2 , Laura Forgione1


, Nicoletta Chicchinelli2


Rossi4, Alessandro Morabito5 Piccirillo7


1 & Nicola Normanno1,2


Laboratory of Pharmacogenomics, Centro di Ricerche Oncologiche di Mercogliano (CROM)-Istituto Nazionale Tumori ‘Fondazione G. Pascale’-IRCCS, Mercogliano (AV), Italy


2


Cell Biology & Biotherapy Unit, Istituto Nazionale Tumori ‘Fondazione G. Pascale’-IRCCS, Naples, Italy


3


Surgical Pathology Unit, Istituto Nazionale Tumori ‘Fondazione G. Pascale’-IRCCS, Naples, Italy


4Division of Medical Oncology, ‘S.G. Moscati’ Hospital, Avellino, Italy 5


Medical Oncology Unit, Thoraco-Pulmonary Department, Istituto Nazionale Tumori ‘Fondazione G. Pascale’-IRCCS, Naples, Italy


6Thoracic Surgery, Thoraco-Pulmonary Department, Istituto Nazionale


Tumori ‘Fondazione G. Pascale’-IRCCS, Naples, Italy 7


Future Oncology 11(11), 1611–1623 (2015).


Clinical Trials Unit, Istituto Nazionale Tumori ‘Fondazione G. Pascale’ -IRCCS, Naples, Italy


The presence of EGFR mutations predicts the sensitivity to EGF receptor (EGFR)- tyrosine kinase inhibitors in a molecularly defined subset of non-small-cell lung carcinoma (NSCLC) patients. For this reason, EGFR testing of NSCLC is required to provide personalized treatment options and better outcomes for NSCLC patients. As surgery specimens are not available in the majority of NSCLC, other currently available DNA sources are small biopsies and cytological samples, providing however limited and low-quality material. In order to address this issue, the use of surrogate sources of DNA, such as blood, serum and plasma samples, which often contains circulating free tumor DNA or circulating tumor cells, is emerging as a new strategy for tumor genotyping.


Access this article at:


www.oncology-central.com/2016/05/23/egfr-mutations-in-lung-cancer- from-tissue-testing-to-liquid-biopsy


, Raffaella Pasquale1


, Matilde Lambiase1 , Renato Franco3


, Gaetano Rocco6 , , Alessia , Antonio , Maria Carmela


Access this article at:


www.oncology-central.com/2016/04/13/nanotechnology-for-enrichment- and-detection-of-circulating-tumor-cells


www.oncology-central.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14